Related references
Note: Only part of the references are listed.Change of charge variant composition of trastuzumab upon stressing at physiological conditions
Baubek Spanov et al.
JOURNAL OF CHROMATOGRAPHY A (2021)
Affimers as anti-idiotypic affinity reagents for pharmacokinetic analysis of biotherapeutics
Hope Adamson et al.
BIOTECHNIQUES (2019)
DrugBank 5.0: a major update to the DrugBank database for 2018
David S. Wishart et al.
NUCLEIC ACIDS RESEARCH (2018)
Affimer proteins inhibit immune complex binding to Fc gamma RIIIa with high specificity through competitive and allosteric modes of action
James I. Robinson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Use of In Vitro Systems To Model In Vivo Degradation of Therapeutic Monoclonal Antibodies
Na Yang et al.
ANALYTICAL CHEMISTRY (2018)
LC-MS Differential Analysis for Fast and Sensitive Determination of Biotransformation of Therapeutic Proteins
Ming Yao et al.
DRUG METABOLISM AND DISPOSITION (2018)
Affimers as an Alternative to Antibodies in an Affinity LC-MS Assay for Quantification of the Soluble Receptor of Advanced Glycation End-Products (sRAGE) in Human Serum
Frank Klont et al.
JOURNAL OF PROTEOME RESEARCH (2018)
Affimer Proteins: Theranostics of the Future?
Stuart Kyle
TRENDS IN BIOCHEMICAL SCIENCES (2018)
Affimer proteins for F-actin: novel affinity reagents that label F-actin in live and fixed cells
Anna Lopata et al.
SCIENTIFIC REPORTS (2018)
Assessment of susceptible chemical modification sites of trastuzumab and endogenous human immunoglobulins at physiological conditions
Ingrid Schmid et al.
COMMUNICATIONS BIOLOGY (2018)
Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle
Lorenzo Gerratana et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2017)
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
Gunter von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Affimers proteins are versatile and renewable affinity reagents
Christian Tiede et al.
ELIFE (2017)
Development of an Affimerantibody combined immunological diagnosis kit for glypican-3
Chunmei Xie et al.
SCIENTIFIC REPORTS (2017)
Interfacing native and non-native peptides: using Affimers to recognise α-helix mimicking foldamers
Irene Arrata et al.
CHEMICAL COMMUNICATIONS (2017)
LC-MS/MS-Based Monitoring of In Vivo Protein Biotransformation: Quantitative Determination of Trastuzumab and Its Deamidation Products in Human Plasma
Peter Bults et al.
ANALYTICAL CHEMISTRY (2016)
Aptamers, antibody scFv, and antibody Fab' fragments: An overview and comparison of three of the most versatile biosensor biorecognition elements
Victor Crivianu-Gaita et al.
BIOSENSORS & BIOELECTRONICS (2016)
The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity
Gabor Toth et al.
MABS (2016)
Techniques for quantitative LC-MS/MS analysis of protein therapeutics: advances in enzyme digestion and immunocapture
Eliza N. Fung et al.
BIOANALYSIS (2016)
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Sandra M. Swain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A search for synergy in the binding kinetics of Trastuzumab and Pertuzumab whole and F(ab) to Her2
Wai-Heng Lua et al.
NPJ BREAST CANCER (2015)
Investigating the Applicability of Antibodies Generated within the Human Protein Atlas as Capture Agents in Immunoenrichment Coupled to Mass Spectrometry
Tove Bostrom et al.
JOURNAL OF PROTEOME RESEARCH (2014)
Trastuzumab (Herceptin)
J. J. Gemmete et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2011)
Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism
Gloria Fuentes et al.
BREAST CANCER RESEARCH (2011)
Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
Werner Scheuer et al.
CANCER RESEARCH (2009)
Affinity separation and enrichment methods in proteomic analysis
Xiangming Fang et al.
JOURNAL OF PROTEOMICS (2008)
mMass data miner: an open source alternative for mass spectrometric data analysis
Martin Strohalm et al.
RAPID COMMUNICATIONS IN MASS SPECTROMETRY (2008)
Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice
Clifford A. Hudis
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Evaluation of the application of sodium deoxycholate to proteomic analysis of rat hippocampal plasma membrane
Jian Zhou et al.
JOURNAL OF PROTEOME RESEARCH (2006)
In vivo deamidation characterization of monoclonal antibody by LC/MS/MS
LH Huang et al.
ANALYTICAL CHEMISTRY (2005)
Identification of multiple sources of charge heterogeneity in a recombinant antibody
RJ Harris et al.
JOURNAL OF CHROMATOGRAPHY B (2001)
Isoaspartate in peptides and proteins: formation, significance, and analysis
DW Aswad et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2000)